LOC728392: A Potential Drug Target and Biomarker (G728392)
LOC728392: A Potential Drug Target and Biomarker
LOC728392 is a unique protein that has been identified as a potential drug target and biomarker. It is a member of the protein kinase C (PKC) family, which is a well-known signaling pathway that plays a crucial role in various cellular processes. PKC is a serine/thrombin-activated enzyme that is involved in the regulation of cell survival, growth, and differentiation. The PKC pathway has been implicated in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.
LOC728392 was first identified as a gene that encodes a protein with multiple potential drug-like molecules. The protein has a molecular weight of approximately 180 kDa and a calculated pI of 1.5. It is expressed in a variety of tissues, including muscle, heart, brain, and liver. LOC728392 has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and survival.
One of the most promising aspects of LOC728392 is its potential as a drug target. The PKC pathway has been implicated in many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Activating the PKC pathway has been shown to promote the growth and survival of cancer cells, and inhibiting it has been shown to be an effective treatment for some neurodegenerative diseases.
LOC728392 has been shown to be involved in the regulation of several key cellular processes that are affected by cancer and neurodegenerative diseases. For example, LOC728392 has been shown to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. In cancer, abnormal cell adhesion can lead to the formation of tumors and the development of invasive cancer.
LOC728392 has also been shown to be involved in the regulation of cell migration, which is the process by which cells move from one location to another in the body. In cancer, abnormal cell migration can lead to the formation of tumors and the development of invasive cancer.
LOC728392 has also been shown to be involved in the regulation of cellular apoptosis, which is the process by which cells die when they have reached a certain level of stress or damage. In cancer, abnormal apoptosis can lead to the survival of cancer cells and the development of invasive cancer.
In addition to its potential role in drug targets, LOC728392 has also been shown to be a potential biomarker for several diseases, including cancer. The PKC pathway is involved in the regulation of many cellular processes, including cell growth, differentiation, and apoptosis. As such, LOC728392 has been shown to be involved in the regulation of cellular processes that are affected by a wide range of diseases, including cancer.
LOC728392 has been shown to be expressed in many different types of cancer, including breast, lung, and ovarian cancer. It has also been shown to be involved in the regulation of cellular processes that are affected by these cancers, including cell adhesion, migration, and apoptosis. These findings suggest that LOC728392 may be a useful biomarker for the diagnosis and treatment of cancer.
In conclusion, LOC728392 is a unique protein that has been identified as a potential drug target and biomarker. Its involvement in the regulation of cellular processes that are affected by cancer and neurodegenerative diseases makes it an attractive target for drug development. Further research is needed to fully understand the role of LOC728392 in these diseases and to develop effective treatments.
Protein Name: Uncharacterized LOC728392
The "LOC728392 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC728392 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC728417 | LOC728485 | LOC728554 | LOC728660 | LOC728688 | LOC728715 | LOC728739 | LOC728743 | LOC728877 | LOC728989 | LOC729086 | LOC729164 | LOC729173 | LOC729218 | LOC729296 | LOC729444 | LOC729609 | LOC729683 | LOC729732 | LOC729737 | LOC729815 | LOC729870 | LOC729887 | LOC729966 | LOC729973 | LOC730098 | LOC730100 | LOC730101 | LOC730183 | LOC730234 | LOC730338 | LOC730668 | LOC90246 | LOC91450 | LOC93429 | LOC93463 | LOC93622 | LOH12CR2 | Long intergenic non-protein coding RNA 1336 | Long intergenic non-protein coding RNA 205 | Long intergenic non-protein coding RNA 266-4, pseudogene | Long-chain-fatty-acid--CoA ligase | LONP1 | LONP2 | LONRF1 | LONRF2 | LONRF3 | LORICRIN | LOX | LOXHD1 | LOXL1 | LOXL1-AS1 | LOXL2 | LOXL3 | LOXL4 | LPA | LPAL2 | LPAR1 | LPAR2 | LPAR3 | LPAR4 | LPAR5 | LPAR6 | LPCAT1 | LPCAT2 | LPCAT3 | LPCAT4 | LPGAT1 | LPIN1 | LPIN2 | LPIN3 | LPL | LPO | LPP | LPP-AS1 | LPP-AS2 | LPXN | LRAT | LRATD1 | LRATD2 | LRBA | LRCH1 | LRCH2 | LRCH3 | LRCH4 | LRCOL1 | LRFN1 | LRFN2 | LRFN3 | LRFN4 | LRFN5 | LRG1 | LRGUK | LRIF1 | LRIG1 | LRIG2 | LRIG2-DT | LRIG3 | LRIG3-DT | LRIT1
